|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group, : Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bristow RE, Santillan A, Salani R,
Diaz-Montes TP, Giuntoli RL II, Meisner BC, Armstrong DK and Frick
KD: Intraperitoneal cisplatin and paclitaxel versus intravenous
carboplatin and paclitaxel chemotherapy for Stage III ovarian
cancer: A cost-effectiveness analysis. Gynecol Oncol. 106:476–481.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozols RF, Bookman MA, du Bois A, Pfisterer
J, Reuss A and Young RC: Intraperitoneal cisplatin therapy in
ovarian cancer: Comparison with standard intravenous carboplatin
and paclitaxel. Gynecol Oncol. 103:1–6. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mukherji S, Ebert MS, Zheng GX, Tsang JS,
Sharp PA and van Oudenaarden A: MicroRNAs can generate thresholds
in target gene expression. Nat Genet. 43:854–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Selbach M, Schwanhäusser B, Thierfelder N,
Fang Z, Khanin R and Rajewsky N: Widespread changes in protein
synthesis induced by microRNAs. Nature. 455:58–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. Embo Molecular Medicine. 4:143–159. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heneghan HM, Miller N and Kerin MJ: MiRNAs
as biomarkers and therapeutic targets in cancer. Curr Opin
Pharmacol. 10:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Volinia S, Bonome T, Calin GA,
Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K,
et al: Genomic and epigenetic alterations deregulate microRNA
expression in human epithelial ovarian cancer. Proc Natl Acad Sci
USA. 105:7004–7009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dahiya N and Morin PJ: MicroRNAs in
ovarian carcinomas. Endocr Relat Cancer. 17:F77–F89. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jayaraman M, Radhakrishnan R, Mathews CA,
Yan M, Husain S, Moxley KM, Song YS and Dhanasekaran DN:
Identification of novel diagnostic and prognostic miRNA signatures
in endometrial cancer. Genes Cancer. 8:566–576. 2017.PubMed/NCBI
|
|
22
|
Xia W, Zhou J, Luo H, Liu Y, Peng C, Zheng
W and Ma W: MicroRNA-32 promotes cell proliferation, migration and
suppresses apoptosis in breast cancer cells by targeting FBXW7.
Cancer Cell Int. 17:142017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang H, Li Y, Zhong X, Luo P, Luo P, Sun
R, Xie R, Fu D, Ma Y, Cong X and Li W: Upregulation of microRNA-32
is associated with tumorigenesis and poor prognosis in patients
with hepatocellular carcinoma. Oncol Lett. 15:4097–4104.
2018.PubMed/NCBI
|
|
24
|
Yan SY, Chen MM, Li GM, Wang YQ and Fan
JG: MiR-32 induces cell proliferation, migration, and invasion in
hepatocellular carcinoma by targeting PTEN. Tumor Biol.
36:4747–4755. 2015. View Article : Google Scholar
|
|
25
|
Latonen L, Scaravilli M, Gillen A,
Hartikainen S, Zhang FP, Ruusuvuori P, Kujala P, Poutanen M and
Visakorpi T: In vivo expression of miR-32 induces proliferation in
prostate epithelium. Am J Pathol. 187:2546–2557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu W, Yang J, Feng X, Wang H, Ye S, Yang
P, Tan W, Wei G and Zhou Y: MicroRNA-32 (miR-32) regulates
phosphatase and tensin homologue (PTEN) expression and promotes
growth, migration, and invasion in colorectal carcinoma cells. Mol
Cancer. 12:302013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang D, Ni Z, Xu X and Xiao J: MiR-32
functions as a tumor suppressor and directly targets EZH2 in human
oral squamous cell carcinoma. Med Sci Monit. 20:2527–2535. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–744. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McIlwain DR, Pan Q, Reilly PT, Elia AJ,
McCracken S, Wakeham AC, Itie-Youten A, Blencowe BJ and Mak TW:
Smg1 is required for embryogenesis and regulates diverse genes via
alternative splicing coupled to nonsense-mediated mRNA decay. Proc
Natl Acad Sci USA. 107:12186–12191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nickless A, Bailis JM and You ZS: Control
of gene expression through the nonsense-mediated RNA decay pathway.
Cell Biosci. 7:262017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
González-Estévez C, Felix DA, Smith MD,
Paps J, Morley SJ, James V, Sharp TV and Aboobaker AA: SMG-1 and
mTORC1 act antagonistically to regulate response to injury and
growth in planarians. PLoS Genet. 8:e10026192012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Du Y, Lu F, Li P, Ye J, Ji M, Ma D and Ji
C: SMG1 acts as a novel potential tumor suppressor with epigenetic
inactivation in acute myeloid leukemia. Int J Mol Sci.
15:17065–17076. 2014. View Article : Google Scholar : PubMed/NCBI
|
